29. (Amended) A biologically active, dimerized polypeptide fusion, comprising:

first and second polypeptide chains, wherein each of said polypeptide chains comprises a non-immunoglobulin polypeptide requiring dimerization for biological activity joined to a dimerizing protein heterologous to said non-immunoglobulin polypeptide.

30. (Amended) The biologically active, dimerized polypeptide fusion of claim 29 which is a homodimer.

31. (Amended) The biologically active, dimerized polypeptide fusion of claim 29 wherein the dimerizing protein of one of said polypeptide chains comprises an immunoglobulin heavy chain constant region.

32. (Amended) The biologically active, dimerized polypeptide fusion of claim 31 wherein the immunoglobulin heavy chain constant region is joined to an immunoglobulin hinge region.

33. (Amended) The biologically active, dimerized polypeptide fusion of claim 31 wherein the immunoglobulin heavy chain constant region is joined to an immunoglobulin variable region.

34. (Amended) The biologically active, dimerized polypeptide fusion of claim 33 wherein the immunoglobulin variable region is selected from the group consisting of V_H, $V\kappa$, and $V\lambda$.

35. (Amended) The biologically active, dimerized polypeptide fusion of claim 29 wherein the dimerizing protein one

of said polypeptide chains comprises an immunoglobulin heavy chain constant region domain selected from the group consisting of C_H1, C_H2, C_H3, and C_H4 of a γ, α, ϵ, μ, or δ class immunoglobulin heavy chain.

36. (Amended) The biologically active, dimerized polypeptide fusion of claim 29 wherein the dimerizing protein of one of said polypeptide chains comprises an immunoglobulin light chain constant region.

37. (Amended) A biologically active, multimerized polypeptide fusion, comprising:

a non-immunoglobulin polypeptide requiring multimerization for biological activity joined to an immunoglobulin light chain constant region; and

an immunoglobulin heavy chain constant region domain selected from the group consisting of C_H1, C_H2, C_H3, and C_H4.

38. (Amended) The biologically active, multimerized polypeptide fusion of claim 37 which is a tetramer comprising four polypeptide fusions each having a non-immunoglobulin polypeptide joined to a multimerizing protein.

39. (Amended) [The] A biologically active, multimerized polypeptide fusion [of claim 37 wherein the multimerizing protein comprises] comprising: a non-immunoglobulin polypeptide requiring multimerization for biological activity joined to an immunoglobulin ~~light~~ heavy chain constant region; and

an immunoglobulin ~~light~~ heavy chain.

40. (Amended) The biologically active, multimerized polypeptide fusion of claim 39 wherein the

immunoglobulin heavy chain constant region is joined to an immunoglobulin hinge region.

41. (Amended) The biologically active, multimerized polypeptide fusion of claim 39 wherein the immunoglobulin heavy chain constant region is joined to an immunoglobulin variable region.

42. (Amended) The biologically active, multimerized polypeptide fusion of claim 41 wherein the immunoglobulin variable region is selected from the group consisting of V_H, Vκ, and Vλ.

43. (Amended) The biologically active, multimerized polypeptide fusion of claim 37 [wherein the] including a multimerizing protein which comprises an immunoglobulin heavy chain constant region domain selected from the group consisting of C_H1, C_H2, C_H3, and C_H4 of a γ, α, ϵ, μ, or δ class immunoglobulin heavy chain.

45. (Amended) The biologically active, heteromultimeric polypeptide fusion, comprising:

a first polypeptide fusion comprising a first non-immunoglobulin polypeptide joined to a first multimerizing protein heterologous to said first non-immunoglobulin polypeptide and a second polypeptide fusion comprising a second non-immunoglobulin polypeptide joined to a second multimerizing protein heterologous to said second non-immunoglobulin polypeptide.

46. (Amended) The biologically active, heteromultimeric polypeptide fusion of claim 45 wherein the first and second non-immunoglobulin polypeptides each comprise an amino

acid sequence selected from the group consisting of (A) the amino acid sequence [of Figures 1A-1D (Sequence ID Numbers 1 and 2)] Sequence ID NO:2, and (B) the amino acid sequence of [Figures 11A-11D (Sequence ID Numbers 35 and 36)] Sequence ID NO:36.

~~47.~~ 48. (Amended) The biologically active, heteromultimeric polypeptide fusion of claim ~~45~~ 46 wherein the first multimerizing protein is different from the second multimerizing protein.

~~48.~~ 49. (Amended) The biologically active, heteromultimeric polypeptide fusion of claim ~~47~~ 48 wherein the first and second non-immunoglobulin polypeptides are the same.

~~49.~~ 50. (Amended) The biologically active, heteromultimeric polypeptide fusion of claim ~~45~~ 46 wherein the first and second multimerizing proteins each comprise an immunoglobulin heavy chain constant region or an immunoglobulin light chain constant region.

~~50.~~ 51. (Amended) The biologically active, heteromultimeric polypeptide fusion of claim ~~45~~ 46 which comprises a first polypeptide fusion having a first non-immunoglobulin polypeptide joined to a first immunoglobulin constant region and a second polypeptide fusion having a second non-immunoglobulin polypeptide fused to a second immunoglobulin constant region different from the first immunoglobulin constant region.

~~51.~~ 52. (Amended) The biologically active, heteromultimeric polypeptide fusion of claim ~~50~~ 51 wherein the first multimerizing protein comprises an immunoglobulin heavy chain constant region and the second multimerizing protein comprises an immunoglobulin light chain constant region.

52. (Amended) The biologically active, heteromultimeric polypeptide fusion of claim 49 wherein one of said multimerizing proteins comprises an immunoglobulin heavy chain constant region joined to an immunoglobulin hinge region.

53. (Amended) The biologically active, heteromultimeric polypeptide fusion of claim 49 wherein one of said multimerizing proteins comprises an immunoglobulin heavy chain constant region joined to an immunoglobulin variable region.

54. (Amended) The biologically active, heteromultimeric polypeptide fusion of claim 53 wherein the immunoglobulin variable region is selected from the group consisting of V_H, $V\kappa$, and $V\lambda$.

55. (Amended) The biologically active, heteromultimeric polypeptide fusion of claim 45 wherein one of said multimerizing proteins comprises an immunoglobulin heavy chain constant region domain selected from the group consisting of C_H1, C_H2, C_H3, and C_H4 of a γ, α, ϵ, μ, or δ class immunoglobulin heavy chain.

56. (Amended) The biologically active, heteromultimeric polypeptide fusion of claim 45 wherein said multimerized polypeptide fusion comprises a first polypeptide fusion comprising a first receptor or receptor domain requiring multimerization for activity joined to a first immunoglobulin constant region and a second polypeptide fusion comprising a second receptor or receptor domain requiring multimerization for activity joined to a second immunoglobulin constant region.